Viking Therapeutics Inc. Common Stock (VKTX)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Viking as a Graham-style analyst: where are the earnings, assets, and margin of safety? Here, there are none in the conventional sense. The company is a clinical-stage biopharmaceutical firm with 65 employees, developing VK2809 and other candidates. It reported no revenue in the filed periods I can see. In fiscal year 2023 (period ended 2023-12-31) it lost $85.9 million; fiscal year 2024 (period ended 2024-12-31), $110.0 million; fiscal year 2025 (period ended 2025-12-31), $359.6 million. The first half of fiscal 2026 was even heavier: Q1 2026 (quarter ended 2026-03-31) lost $158.3 million, or $1.37 per diluted share, and Q2 2026 (quarter ended 2026-06-30) lost $128.0 million, or $1.10. Trailing free cash flow is -$418.4 million. At a $26.65 close on 2026-10-13, market cap is $3.1 billion; FairStock calculates P/E -5.71, P/B 7.61, ROE -88.85%, ROCE -51.86%, Piotroski 0/9, and FairStock Score 23/100. The balance sheet has little debt (D/E 0.01), and Altman Z 14.32 suggests low near-term bankruptcy risk by that measure, but equity is being consumed by trials. The Lynch screen finds no category because losses occurred each of the last four years. A true moat would require approved products, pricing power, and recurring cash flows. Viking has none yet; it has scientific optionality. That can be valuable if trials succeed, but it is not a value investment in the Graham sense. The price is a call option on clinical data, and the margin of safety is thin relative to current losses.

In plain English: Viking Therapeutics is a small drug-development company working on experimental medicines for metabolic and endocrine diseases. It has no product sales yet, and its losses have grown to hundreds of millions of dollars a year, so the business looks weak on current numbers. At $26.65, the price reflects hope for future trial success rather than today’s results, making it look expensive versus its current financials.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer